References
-
1
Lanas A, Garcia-Rodriguez L A, Arroyo M T. et al .
Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants.
Am J Gastroenterol.
2007;
102
507-515
-
2
Chan F K, Wong V W, Suen B Y. et al .
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomized trial.
Lancet.
2007;
369
1621-1626
-
3
Abraham N S, El-Serag H B, Hartman C. et al .
Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.
Aliment Pharmacol Ther.
2007;
25
913-924
-
4
Take S, Mizuno M, Ishiki K. et al .
Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases.
J Gastroenterol.
2007;
42
21-27
-
5
Vaira D, Zullo A, Vakil N. et al .
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial.
Ann Intern Med.
2007;
146
556-563
-
6
Chan F K, Hung L C, Suen B Y. et al .
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
N Engl J Med.
2002;
347
2104-2110
-
7
Chan F K, Chung S C, Suen B Y. et al .
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
N Engl J Med.
2001;
344
967-973
-
8
Lai K C, Chu K M, Hui W M. et al .
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Am J Med.
2005;
118
1271-1278
-
9
Hoer A, Gothe H, Schiffhorst G. et al .
Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalization due to peptic ulcer disease.
Pharmacoepidemiol Drug Saf.
2007;
16
854-858
-
10
Garcia-Rodriguez L A, Barreales Tolosa L.
Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population.
Gastroenterology.
2007;
132
498-506
-
11
Lanas A, Garcia-Rodriguez L A, Arroyo M T. et al .
Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.
Gut.
2006;
55
1731-1738
-
12
Bombardier C, Laine L, Reicin A. et al .
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
N Engl J Med.
2000;
343
1520-1528
-
13
Solomon D H, Avorn J, Sturmer T. et al .
Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Arthritis Rheum.
2006;
54
1378-1389
-
14
Fries S, Grosser T, Price T S. et al .
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Gastroenterology.
2006;
130
55-64
-
15
Uemura N, Okamoto S, Yamamoto S. et al .
Helicobacter pylori infection and the development of gastric cancer.
N Engl J Med.
2001;
345
784-789
-
16
Rugge M, Meggio A, Pennelli G. et al .
Gastritis staging in clinical practice: the OLGA staging system.
Gut.
2007;
56
631-636
-
17
Watabe H, Mitsushima T, Yamaji Y. et al .
Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study.
Gut.
2005;
54
764-768
-
18
Kimura K, Takemoto T.
An endoscopic recognition of the atrophic border and its significance in chronic gastritis.
Endoscopy.
1969;
3
87-97
-
19
Nagahara A, Miwa H, Ogawa K. et al .
Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
Helicobacter.
2000;
5
88-93
-
20
Treiber G, Ammon S, Schneider E. et al .
Amoxicillin / metronidazole / omeprazole / clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication.
Helicobacter.
1998;
3
54-58
-
21
Sugimoto M, Furuta T, Shirai N. et al .
Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.
Helicobacter.
2007;
12
317-323
D. Y. Graham, MD
Michael E. DeBakey Veterans Affairs Medical Center
RM 3A-320 (111D)2002 Holcombe Boulevard
Houston
TX 77 030
USA
Fax: +1-713-790-1040
Email: dgraham@bcm.tmc.edu
